• Sulfaphenazole Restores Vasodilation in Diabetic Mice

  2026-09-09

  The reference study identified CYP 2C monooxygenase activity as a modifiable source of oxidative stress contributing to endothelial dysfunction in diabetic db/db mice. Eight weeks of sulfaphenazole treatment restored acetylcholine-mediated vasodilation, reduced plasma 8-isoprostane, and increased a nitric oxide-related readout without lowering blood glucose, linking CYP inhibition to vascular redox control.

• BX795: Translating Kinase Mechanism into Better Data

  2026-09-09

  BX795 is more than a PDK1 inhibitor: its activity across PDK1, TBK1, and IKKε creates a strategic platform for connecting kinase biochemistry, cancer phenotypes, and innate immune signaling while preserving translational rigor.

• Levofloxacin Workflows for Bacterial and Bone Assays

  2026-09-08

  Levofloxacin supports a unified workflow spanning bacterial DNA replication studies, osteoblast growth inhibition assays, calcium deposition inhibition, and cartilage metabolism research. This guide converts its mechanism and product-specific solubility data into practical experimental designs, controls, and troubleshooting decisions.

• Tacrolimus (FK506) Workflow for Cytokine Assays

  2026-09-07

  Tacrolimus (FK506) provides a highly potent route to dissect calcineurin-dependent T-cell activation, cytokine release, and immune response suppression. This practical guide connects cell-based assay design with transplantation immunology research and shows how the metabolic-stress findings of a 2024 reference study can inform, but not replace, careful pathway controls.

• Sulfaphenazole C4131 for Reliable Cell Assays

  2026-09-07

  Learn how Sulfaphenazole (SKU C4131) can help laboratories separate solvent, cytotoxicity, CYP2C9 inhibition, and antibacterial effects in reproducible cell-based workflows. This scenario-driven guide links concentration selection, controls, interpretation, and product choice to documented quantitative data.

• C8-HSL Drives Lung Cancer Signaling in H460 Cells

  2026-09-05

  The 2026 FASEB Journal study identifies the bacterial quorum-sensing molecule C8-HSL as a regulator of lung cancer cell behavior, linking microbial signaling to PI3K/AKT/ERK activation, cell-cycle progression, migration, and invasion. Its findings provide a mechanistic basis for investigating bacterial metabolites in lung tumor biology while highlighting the need for validation in physiologically relevant models.

• Mitomycin C: A Translational DNA-Damage Stress Test

  2026-09-04

  Mitomycin C is more than a cytotoxic reagent: it is a mechanistic probe for DNA damage, replication stress, apoptosis competence, and treatment resistance. This thought-leadership guide shows how translational researchers can use the antitumor antibiotic to connect molecular mechanism with experimental design, while recognizing the limits of cross-model interpretation.

• Estradiol Benzoate: From Binding to Assay Design

  2026-09-04

  Estradiol Benzoate is a high-affinity estrogen receptor alpha agonist for rigorous receptor and pathway studies. This article connects its physicochemical handling and ERα assay design with a structure-based screening framework, clarifying what computational evidence can—and cannot—tell researchers.

• Mitomycin C Workflows for Cancer Research

  2026-09-04

  Build reproducible DNA damage, apoptosis, and TRAIL-sensitization assays with Mitomycin C, from DMSO stock preparation through mechanistic validation. The workflow also shows how findings from an HCC immunotherapy study can inform immune-aware assay design without overstating what the reference demonstrated.

• Cyanine 5-dCTP for Fluorescent DNA Labeling

  2026-09-03

  Cyanine 5-dCTP is a Cy5-labeled deoxycytidine triphosphate for enzymatic DNA labeling and fluorescence-based nucleic acid detection. Its product specifications support controlled handling, while recent tetrahedral DNA framework research provides a useful benchmark for improving enzymatic oligonucleotide synthesis rather than direct validation of this reagent.

• Chenodeoxycholic Acid and FXR in Renal Translation

  2026-09-02

  Chenodeoxycholic Acid is more than a bile acid metabolism tool: it offers a pharmacological route into FXR-dependent transcriptional control. New preclinical evidence connects CDCA to the FXR–KLF11 axis, suppression of JAK2/STAT3 signaling, and protection against contrast-induced acute kidney injury. This thought-leadership guide explains how translational researchers can validate that mechanism, manage compound-handling variables, distinguish pharmacology from causality, and position CDCA intelligently across cholesterol metabolism research, nuclear receptor signaling, and renal injury models.

• Clozapine N-oxide: DREADD Workflow and Controls

  2026-09-02

  Learn how Clozapine N-oxide supports controlled DREADD activation, neuronal activity modulation, and GPCR signaling research. This practical guide combines assay setup, concentration planning, controls, troubleshooting, and a careful translation of muscarinic receptor findings from prostate cancer research.

• Mitomycin C for DNA-Damage Assay Design

  2026-09-01

  Mitomycin C is an antitumor antibiotic whose DNA-adduct chemistry can be used to design more discriminating cancer and host-cell assays. This article connects DNA replication inhibition with CRISPR-based VZV research while defining controls that separate target-specific biology from generalized cytotoxicity.

• Cathepsin B inhibitor CA-074: Assay Guide

  2026-09-01

  This scenario-driven guide explains how Cathepsin B inhibitor CA-074 (SKU A1926) can improve the interpretation of cell viability, cytotoxicity, proliferation, and metastasis experiments. It combines selectivity data, assay controls, formulation guidance, and practical vendor-selection criteria for reproducible laboratory workflows.

• QRICH1 Links ER Stress to HMGB1 Release in HBV

  2026-08-31

  The reference study identifies QRICH1 as a functional effector connecting endoplasmic reticulum stress with HMGB1 translocation and secretion during HBV-associated hepatic fibrosis. Its combined mouse, human-specimen, histological, protein, and transcriptional analyses suggest that HBV-associated SIRT6 dysregulation and QRICH1-dependent HMGB1 transcription form complementary parts of this inflammatory pathway.

8519 records 1/568 page Next 12345 下5页 Last page